Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development
Alpine Immune Sciences Inc
Atox Bio Ltd
Avacta Life Sciences Ltd
Bristol-Myers Squibb Co
Five Prime Therapeutics Inc
Imugene Ltd
OSE Immunotherapeutics
Regeneron Pharmaceuticals Inc
TheraMAB LLC
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles
ALPN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALPN-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclol Antibody to Target CD28 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FPT-155 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FR-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Target ICOS, CD28 and NCR3LG1 for Colon Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lulizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Target CD278, CD28 and HER2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Proteins to Agonize CD28 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-5678 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reltecimod sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAB-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD28 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Alpine Immune Sciences presents ALPN-101 phase 1 healthy volunteer study data and details of upcoming phase I/II BALANCE GVHD study at the 61st American Society of Hematology annual meeting
Nov 12, 2019: Alpine Immune Sciences presents new ALPN-101 preclinical data at the 2019 American College of Rheumatology (ACR) Annual Meeting
Nov 09, 2019: Five Prime Therapeutics presents initial safety data from the phase 1 trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting
Nov 08, 2019: Alpine Immune Sciences presents new preclinical data at The Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
Nov 06, 2019: Alpine Immune Sciences announces oral presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and Exposition
Oct 30, 2019: Alpine Immune Sciences completes enrollment of phase I study of ALPN-101 and announces third quarter conference call
Oct 02, 2019: Alpine Immune Sciences announces upcoming scientific presentation of ALPN-101 at ACR/ARHP 2019 Annual Meeting
Oct 02, 2019: Alpine Immune Sciences announces upcoming scientific presentation on ALPN-202 at SITC 2019 Annual Meeting
Jun 18, 2019: Atox Bio announces exercise by BARDA of next option period to support continued development of reltecimod for NSTI
Apr 09, 2019: OSE Immunotherapeutics announces issuance of Cadian patent and notice of allowance of U.S. patent protecting CD28-Antagonist Immunotherapy FR104
Feb 19, 2019: Alpine Immune Sciences presents preclinical ALPN-101 GvHD data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)
Feb 14, 2019: Atox Bio announces appointment of Robert Greif as chief commercial officer
Feb 12, 2019: Alpine Immune treats first patient in Phase I trial of ALPN-101
Dec 03, 2018: Alpine Immune sciences showcases key preclinical data at 60th American Society of Hematology Annual Meeting and Exposition
Nov 29, 2018: Alpine Immune Sciences announces ALPN-101 data to be included in oral presentation at 60th American Society of Hematology Annual Meeting and Exposition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Alpine Immune Sciences Inc, H2 2019
Pipeline by Atox Bio Ltd, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Five Prime Therapeutics Inc, H2 2019
Pipeline by Imugene Ltd, H2 2019
Pipeline by OSE Immunotherapeutics, H2 2019
Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Pipeline by TheraMAB LLC, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019